BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Release

BioDelivery Sciences to Host Conference Call and Webcast of Fourth Quarter and Year End 2014 Results on Monday, March 16

March 9, 2015 at 12:00 AM EDT

RALEIGH, N.C., March 9, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its fourth quarter and year end 2014 financial results after the close of the market and host a conference call and webcast on Monday, March 16, 2015.

 

Conference Call & Webcast

 

Monday, March 16, 2015 @ 5:00pm Eastern/2:00pm Pacific

Domestic:

888-510-1785

International:

719-457-1035 

Conference ID:

1385073

Webcast:

http://public.viavid.com/player/index.php?id=113525

   

Replay available following the call:

Domestic:

877-870-5176

International:

858-384-5517

Conference ID:

1385073

   

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.  BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.  BDSI's headquarters is located in Raleigh, North Carolina.  

   

For more information, please visit or follow us:

Internet:

www.bdsi.com

Facebook:

Facebook.com/BioDeliverySI

Twitter:

@BioDeliverySI

   

Cautionary Note on Forward-Looking Statements

This press release, the conference call described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the conference described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the commercial launch of BUNAVAIL and the Company's clinical trials for, and FDA review of, the Company's products in development) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc  All other trademarks and tradenames are owned by their respective owners.

© 2015 BioDelivery Sciences International, Inc.  All rights reserved.

Contacts

Investors: 
Matthew P. Duffy  
Managing Director 
LifeSci Advisors, LLC 
212-915-0685 
matthew@lifesciadvisors.com

Al Medwar 
Vice President, Marketing and Corporate Development 
BioDelivery Sciences International, Inc. 
919-582-9050 
amedwar@bdsi.com

Logo - http://photos.prnewswire.com/prnh/20110217/CL49801LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biodelivery-sciences-to-host-conference-call-and-webcast-of-fourth-quarter-and-year-end-2014-results-on-monday-march-16-300047116.html

SOURCE BioDelivery Sciences International, Inc.